Tags

Type your tag names separated by a space and hit enter

[Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab].
Rinsho Ketsueki. 2020; 61(6):612-616.RK

Abstract

Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy caused by the human T-cell lymphotropic virus, type I and it has an extremely poor prognosis. A 66-year-old man with severe hepatic damage, massive pleural effusion and ATL cell infiltration-induced ascites was referred to our department. Reduced-intensity cytotoxic chemotherapy was attempted, but could not continue due to persistent hyperbilirubinemia. Laboratory results also showed elevated lactate dehydrogenase (LDH) and serum albumin levels were profoundly decreased. A humanized monoclonal antibody against chemokine receptor type 4 (CCR4), mogamulizumab (Moga), was thereby challenged and it successfully resolved the hepatic damage. Finally, a standard dose of chemotherapy could be administered, and it induced a complete remission. The patient is still in remission more than three years after the final dosage of standard chemotherapy. These results indicate that Moga, whose pharmacokinetics are not significantly influenced by hepatic function or serum albumin, could be a promising treatment option for patients with ATL complicated by severe hepatic damage due to infiltration of ATL cells.

Authors+Show Affiliations

Department of Hematology and Rheumatology, Kagoshima University Hospital.Department of Hematology and Rheumatology, Kagoshima University Hospital.Department of Hematology and Rheumatology, Kagoshima University Hospital.Department of Hematology and Rheumatology, Kagoshima University Hospital.Department of Hematology and Rheumatology, Kagoshima University Hospital.Department of Hematology and Rheumatology, Kagoshima University Hospital.Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University.Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University.Department of Hematology and Rheumatology, Kagoshima University Hospital.Department of Hematology and Rheumatology, Kagoshima University Hospital. Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University.Department of Hematology and Rheumatology, Kagoshima University Hospital. Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University.

Pub Type(s)

Case Reports
Journal Article

Language

jpn

PubMed ID

32624533

Citation

Shodai, Aya, et al. "[Adult T-cell Leukemia-lymphoma With Severe Hepatic Damage and Fluid Retention Successfully Treated With Mogamulizumab]." [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, vol. 61, no. 6, 2020, pp. 612-616.
Shodai A, Inoue H, Kamada Y, et al. [Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab]. Rinsho Ketsueki. 2020;61(6):612-616.
Shodai, A., Inoue, H., Kamada, Y., Fujino, S., Tabuchi, T., Arima, N., Uchida, Y., Hachiman, M., Nakamura, D., Yoshimitsu, M., & Ishitsuka, K. (2020). [Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 61(6), 612-616. https://doi.org/10.11406/rinketsu.61.612
Shodai A, et al. [Adult T-cell Leukemia-lymphoma With Severe Hepatic Damage and Fluid Retention Successfully Treated With Mogamulizumab]. Rinsho Ketsueki. 2020;61(6):612-616. PubMed PMID: 32624533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab]. AU - Shodai,Aya, AU - Inoue,Hirosaka, AU - Kamada,Yuhei, AU - Fujino,Satoshi, AU - Tabuchi,Tomohisa, AU - Arima,Naosuke, AU - Uchida,Yuichiro, AU - Hachiman,Miho, AU - Nakamura,Daisuke, AU - Yoshimitsu,Makoto, AU - Ishitsuka,Kenji, PY - 2020/7/7/entrez PY - 2020/7/7/pubmed PY - 2020/7/16/medline KW - ATL KW - Hyperbilirubinemia KW - Hypoalbuminemia KW - Mogamulizumab SP - 612 EP - 616 JF - [Rinsho ketsueki] The Japanese journal of clinical hematology JO - Rinsho Ketsueki VL - 61 IS - 6 N2 - Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy caused by the human T-cell lymphotropic virus, type I and it has an extremely poor prognosis. A 66-year-old man with severe hepatic damage, massive pleural effusion and ATL cell infiltration-induced ascites was referred to our department. Reduced-intensity cytotoxic chemotherapy was attempted, but could not continue due to persistent hyperbilirubinemia. Laboratory results also showed elevated lactate dehydrogenase (LDH) and serum albumin levels were profoundly decreased. A humanized monoclonal antibody against chemokine receptor type 4 (CCR4), mogamulizumab (Moga), was thereby challenged and it successfully resolved the hepatic damage. Finally, a standard dose of chemotherapy could be administered, and it induced a complete remission. The patient is still in remission more than three years after the final dosage of standard chemotherapy. These results indicate that Moga, whose pharmacokinetics are not significantly influenced by hepatic function or serum albumin, could be a promising treatment option for patients with ATL complicated by severe hepatic damage due to infiltration of ATL cells. SN - 0485-1439 UR - https://www.unboundmedicine.com/medline/citation/32624533/[Adult_T-cell_leukemia-lymphoma_with_severe_hepatic_damage_and_fluid_retention_successfully_treated_with_mogamulizumab] L2 - https://dx.doi.org/10.11406/rinketsu.61.612 DB - PRIME DP - Unbound Medicine ER -